CytomX Therapeutics, Inc.

Founded in 2008, CytomX Therapeutics, Inc. leads the way in oncology-focused biopharmaceuticals from its headquarters in South San Francisco. The company designs “conditionally activated” biologics that only trigger once they reach the specific environment of a tumor. This localized approach allows the medicine to attack cancer cells directly while protecting healthy tissue from unnecessary damage.

The core of this innovation involves the proprietary Probody platform. This technology helps scientists validate targets for antibody-drug conjugates and expands the therapeutic window for T-cell engagers in solid tumors. Beyond these oncology efforts, the team explores preclinical applications for the Probody platform in medical fields outside of cancer research.

The current pipeline includes several innovative candidates like CX-904, a bispecific antibody that bridges tumor cells and T cells to trigger an immune response. To complement this, the company develops CX-2051 and CX-2029, which function as activated ADCs for specific epithelial cancers. The portfolio also features CX-801, a specialized cytokine, and BMS-986288, a modified version of the immunotherapy drug ipilimumab.

To accelerate these breakthroughs, CytomX maintains strategic collaborations with industry leaders such as Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. A specific agreement with Merck also enables the testing of CX-801 alongside the well-known therapy KEYTRUDA. By combining internal innovation with global partnerships, CytomX continues to redefine how the medical community treats complex cancers.